Kudo, M. (2016). Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma. Liver Cancer.
Chicago Stili AlıntıKudo, M. "Regorafenib As Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma." Liver Cancer 2016.
MLA AlıntıKudo, M. "Regorafenib As Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma." Liver Cancer 2016.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..